Timo Vogt

CTLA4 methylation predicts response to anti–PD-1 and anti–CTLA-4 immunotherapy in melanoma patients

Diane Goltz, Heidrun Gevensleben, Timo Vogt et al. · JCI Insight · 2018 · 87 citations · Full text

Immunology, Immunoediting, Pathology +21

Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma

Tobias A.W. Holderried, Luka de Vos, Emma Bawden et al. · Clinical Epigenetics · 2019 · 83 citations · Full text

Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma

Anne Fröhlich, Judith Sirokay, Simon Fietz et al. · EBioMedicine · 2020 · 65 citations · Full text

<i>PD-L1</i> (<i>CD274</i>) and <i>PD-L2</i> (<i>PDCD1LG2</i>) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas

Alina Franzen, Timo Vogt, Tim Müller et al. · Oncotarget · 2017 · 58 citations · Full text

Detailed analysis of adenosine A2a receptor (<i>ADORA2A</i>) and CD73 (5′-nucleotidase, ecto,<i>NT5E</i>) methylation and gene expression in head and neck squamous cell carcinoma patients

Timo Vogt, Heidrun Gevensleben, Jörn Dietrich et al. · OncoImmunology · 2018 · 27 citations · Full text